|
41.
Из
личных бесед с автором.
42.
Steven Jacober, “Ames Redefines Itself at $2 Billion," Discount
Merchandiser, August 1988, 22; Peter Hisey, “Herb Gilman: ‘The Concept Is So
Simple,’” Discount Store News
27.
no. 11 (TVIay 23, 1988): 49.
Стадия 2: неконтролируемое стремление к большему
43.
Ames Department Stores, Inc., “Letter to Shareholders,” 1988 Annual
Report to Stockholders (Rocky Hill, CT: Ames Department Stores, Inc., 1989);
Eric N. Berg, “Ames’s Rocky Retailing Marriage," New York Times, April 11,
1990.
44.
Источник: ©2006 CRSP Центр изучения котировок ценных бумаг
Высшей школы бизнеса Чикагского университета. Авторские права
защищены,
www.crsp.chicagobooth.edu
.
45.
Mike DufT, “Discount Veteran Ames to Liquidate After 44 Years,” DSN
Retailing Today 41, no. 16 (August 26, 2002): 1.
46.
Ames Department Stores, Inc., “Letter to Shareholders," 1988 Annual
Report to Stockholders (Rocky Hill, CT: Ames Department Stores, Inc., 1989):
Joseph Pereira, “Digesting Zayre Gives Ames Heartburn,” Wall Street Joumalf
December 28, 1989; Eric N. Berg, "Ames’s Rocky Retailing Marriage," New
York Times, April 11,1990; Pete Hisey, “What Went Wrong at Ames?"
Discount Store News 29, no. 9 (May 7, 1990): 1.
47. Motorola, Inc., 1995 Summary Annual Report (Schaumburg, IL:
Motorola, Inc., 1996).
48.
John Simons, ‘‘Will R&D Make Merck Hot Again?" Fortune, July 8,
2002, 89.
49.
‘‘HP Files 5,000 Patent Applications Worldwide in 2001," HP Press
Release (Palo Alto: Hewlett-Packard Company), February 8, 2002.
50.
Alan Farnham, “America’s Most Admired Company," Fortune, February
7,1994, 50: Marshall Loeb, "How To Grow A New Product Every Day,"
Fortune, November 14, 1994, 269.
51.
“Where Do They Get All Those Ideas?” Machine Design, January 26,
1995, 40; Lornet Turnbull, "Ohio-Based Rubbermaid Inc. Heeds Findings
from Consumer Focus Groups,” Akron Beacon Journal, February 18, 1996.
52.
Wolfgang R. Schmitt, “A Growth Strategy,” Executive Excellence,
August 1994,17; Tricia Welsh, “Best and Worst Corporate Reputations,"
Fortune, February 7, 1994, 58; Alan Famham, “America’s Most Admired
Company,” Fortune, February 7, 1994, 50; Marshall Loeb, “How To Grow A
New Product Every Day,” Fortune, November 14,
1994, 269; Lomet Turnbull, “Ohio-Based Rubbermaid Inc. Heeds Findings
from Consumer Focus Groups," Akron Beacon Journal, February 18,1996.
53.
Lee Smith, "Rubbermaid Goes Thump,” Fortune, October 2, 1995, 90;
Geoffrey Colvin, “From the Most Admired to Just Acquired: How Rubbermaid
Managed to Fail,” Fortune, November 23, 1998, 32.
54.
Glen Gamboa, “Rubbermaid Corp. Is Proposing a Nice, Neat Solution,”
Akron Beacon Journal, October 22, 1998; Glen Gamboa,
“Rubbermaid Seeks Boost Through ’Solutions’ Marketing," Akron Beacon
Journal, July 28, 1997; Raju Narisetti, “Rubberrnaid’s Plan to Buy Graco Is
Eclipsed by Poor Profit Forecast," Wall Street Journal, September 5, 1996;
“Rubbermaid Completes Acquisition,” Discount Store News 35, no. 21
(November 4, 1996): 43; Claudia
H. Deutsch, “A Giant Awakens, To Yawns: Is Rubbermaid Reacting Too
Late?” New York Times, December 22, 1996; Matt Murray, “Rubbermaid Tries
to Regain Lost Stature,” Wall Street Journal, December 6, 1995; Susan Sowa,
“Restructuring May Salvage Rubbermaid,” Rubber &. Plastics News 25, no. 10
(December 18, 1995): 7; Lomet Turnbull, “Ohio-Based Rubbermaid Inc. Heeds
Findings from Consumer Focus Groups,” Akron Beacon Journal, February 18,
1996.
55.
Geoffrey Colvin, “From the Most Admired to Just Acquired: How
Rubbermaid Managed to Fail,” Fortune, November 23, 1998, 32;
Glenn Gamboa, “Rubbermaid Corp. Is Proposing a Nice, Neat Solution,"
Akron Beacon Journal, August 6. 1997; “Buy Merges Rubbermaid’s Products.
Newell’s Management." Akron Beacon Journal. October 22. 1998; Claudia H.
Deutsch, “Newell Buying Rubbermaid in $5.8 Billion Deal,” New York Times,
October 22,
1998.
56.
Amy Barrett and Larry Armstrong, “Merck Takes Some Growth Pills,"
BusinessWeek, October 12, 1998, 78; Gardiner Harris, “Cold Turkey: How
Merck Intends to Ride Out a Wave of Patent Expirations,” Wall Street Journal,
February 9, 2000.
57.
Clark Gilbert and Ratna G. Sarkar, “Merck: Conflict and Change,”
Harvard Business School, case study #9-805-079 (Boston: Harvard Business
School Publishing, 2005).
58. Amy Barrett and Larry Armstrong, “Merck Takes Some Growth Pills,"
BusinessWeek, October 12,1998, 78.
59. Merck & Co., Inc., Merck 1998 Annual Report (Whitehouse Station, NJ:
Merck & Co., Inc., 1999), 3.
60. Merck & Co., Inc., Merck 1999 Annual Report (Whitehouse Station. NJ:
Merck & Co., Inc., 2000); John Simons and David Stipp. “Will Merck Survive
Vioxx?" Fortune, November 1, 2004.90.
61. Eduardo Ortiz, “Market Withdrawal of Yioxx: Is It Time to Rethink the
Use of COX-2 Inhibitors?" Journal of Managed Care Pharmacy'
10, no. 6 (November/December 2004): 551—554: Claire Bombardier. Loren
Laine, Alise Reicin. et al. for the VIGOR Study Group. “Comparison of Upper
Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients With
Rheumatoid Arthritis." New England Journal of Medicine 343, no. 21
(November 23. 2000): 1520—1528.
http://content.nej
m.org/cgi/content/full/
343/21/1520.
62.
Peter S. Kim and Alise S. Reicin. “Refecoxib, Merck and the FDA." New
England Journal of Medicine 351. no. 27 (December 30, 2004): 28 75—28 78;
John Simons and David Stipp, “Will Merck Survive Yioxx?" Fortune,
November 1. 2004, 90.
63.
Merck & Co., Inc., Annual Report 2002 (Whitehouse Station. NJ: Merck
& Co., Inc., 2003); Merck & Co.. Inc., Annual Report 2004 (Whitehouse
Station, NJ: Merck & Co., Inc., 2005); Susan Dentzer. “Drug Failure." Online
NewsHour, November 18, 2004, http://www.pbs.oi)£/ newshour/bb/health/j u ly-
dec04/vioxx n-i&html.
64.
Eric J. Topol, “Failing the Public Health — Rofecoxib, Merck, and the
FDA," New England Journal of Medicine 351, no. 17 (October 21.
2004): 1701 — 1709; Debabrata Mukheijee, Steven E. Nissen, and Eric J.
Topol, “Risk of Cardiovascular Events Associated with Selective COX-2
Inhibitors,” Journal of the American Medical Association 286, no. 8 (August 22,
2001): 954—959; Daniel H. Solomon, Sebastian Schneeweiss, Robert J. Glynn,
et al., “Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute
Myocardial Infarction in Older Adults," Circulation 109 (April 19, 2004): 2068
—2073,
http://circ.ahajoumals.org/cgi/content
/full/109/17/2068.
65.
Peter S. Kim and Alise S. Reicin, “Rofecoxib, Merck and the FDA,"
New England Journal of Medicine 351, no. 27 (December 30, 2004): 2875-2878.
66. Merck & Co., Inc., Annual Report 2004 (Whitehouse Station, NJ: Merck
& Co., Inc., 2005), 21.
67.
Brooke A. Masters and Marc Kaufman, “Painful Withdrawal for Makers
of Yioxx,” Washington Post, October 18, 2004.
68. Christopher Rowland, “CEO Defends Merck on Vioxx: Confirmation of
Woes
Came
‘Out
of
Blue,'"
Boston
Globe,
October
9,
2004,
http://www.boston.com/business/articles/2GQ4/lo/Q9/ceo_defends_
merck_on_vioxx; Merck &
Co.,
Inc.
“Company
Statements,"
VIOXX®
(rofecoxib)InformationCenter,http//
www.merck.com/newsroom/
vioxx/archive.html#company_statements.
Do'stlaringiz bilan baham: |
